EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SNAP‐Tag–Based Recombinant Photoimmunotherapeutic Agents for the Selective Detection and Killing of Light‐Accessible Melanotransferrin‐Expressing Melanoma and Triple‐Negative Breast Cancer

Suzanne Hippolite Magagoum iD, Fleury Augustin Nsole Biteghe iD, Gael Tchokomeni Siwe iD, Dirk Lang iD, Nkhasi Lekena iD, Stefan Barth iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70912 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Suzanne Hippolite Magagoum und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Biotechnology and Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape To…. Hauptthemen laut MEDLINE: Immunotherapy, Melanoma, Photosensitizing Agents, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: South African Research Chairs Initiative of the Department of Science and Technology (DST), National Research Foundation, University of Cape Town.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melanoma and triple negative breast cancer (TNBC) represent the most aggressive skin and breast cancer subtypes and are associated with poor diagnostic and limited therapeutic options leading to poor prognosis. Melanotransferrin/p97 (MTf), initially identified as a tumor‐associated antigen (TAA) in melanoma, is overexpressed in various solid tumors, including TNBC. Beyond its high differential expression and dreadful tumorigenic impact, MTf is also associated with chemoresistance development, and its inhibition significantly hampers tumor progression, making MTf a promising target for effective targeted therapies. Near‐infrared photoimmunotherapy (NIR‐PIT) is an approach that combines the precision of antibodies directed against specific TAA with the phototoxic effects of a light‐sensitive photosensitizer (IR700), activated by near‐infrared (NIR) light irradiation. This study aimed to generate a novel photoimmunoconjugate to specifically destroy MTf‐positive melanoma and TNBC cells in vitro following NIR light irradiation.

Methods

A single‐chain variable fragment (scFv) assembled from anti‐MTf antibody L49 was recombinantly fused with the SNAP‐tag protein (L49(scFv)‐SNAP), capable of irreversible and autocatalytic conjugation to any O(6)‐benzylguanine (BG) substrate in a 1:1 stoichiometry. Purified full‐length SNAP‐tag–based fusion protein (L49(scFv)‐SNAP‐tag) was either conjugated to a BG‐modified fluorescent imaging agent (Alexa 488) to specifically assess its selective binding to MTf‐expressing cell lines via confocal imaging and flow cytometry or to a BG‐modified light‐sensitive photosensitizer (IR700) to evaluate its phototoxic properties using an XTT cell viability assay.

Results

The selective binding and internalization of L49(scFv)‐SNAP‐Alexa 488 towards MTf‐positive melanoma and TNBC cell lines were successfully demonstrated with MTF expression percentages ranging from 52.8 to 83.1. Once confirmed, dose‐dependent phototoxicity of L49(scFv)‐SNAP‐IR700 was achieved on illuminated MTf‐positive cell lines showing IC 50 values in the nanomolar range (2.20–5.24 nM).

Conclusion

This study highlights the therapeutic potential of MTf as a promising target for the diagnosis as well as selective and efficient elimination of NIR‐light‐accessible melanoma and TNBC by NIR‐PIT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyMelanomaPhotosensitizing AgentsTriple Negative Breast NeoplasmsFemaleHumansCell Line, TumorImmunoconjugatesSingle-Chain AntibodiesHEK293 CellsMART-1 Antigen

Stichwörter der Autor:innen

NIR‐PITSNAP‐tag–based antibody fusion proteinmelanomamelanotransferrinsingle‐chain antibody fragment (scFv)triple negative breast cancer

Substanzen

ImmunoconjugatesMLANA protein, humanPhotosensitizing AgentsSingle-Chain AntibodiesMART-1 Antigen

Autor:innen und Institutionen

  • Medical Biotechnology and Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa.
  • Department of Chemistry and Chemical Biology, College of Science, Northeastern University, Boston, Massachusetts, USA.
  • Division of Physiological Sciences, Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Department of Integrative Biomedical Sciences, Faculty of Health Sciences, South African Research Chair in Cancer Biotechnology, University of Cape Town, Cape Town, South Africa.

ORCID-Profile: Suzanne Hippolite Magagoum, Fleury Augustin Nsole Biteghe, Gael Tchokomeni Siwe, Dirk Lang, Nkhasi Lekena, Stefan Barth

Förderung

  • South African Research Chairs Initiative of the Department of Science and Technology (DST)
  • National Research Foundation
  • University of Cape Town
  • Faculty of Health Sciences
  • University of Capetown
  • Faculdade de Ciências da Saúde, Universidade de Macau
  • Department of Science and Technology, Republic of South Africa

Zitieren

APA

Magagoum, S. H., Biteghe, F. A. N., Siwe, G. T., Lang, D., Lekena, N., & Barth, S. (2025). SNAP‐Tag–Based Recombinant Photoimmunotherapeutic Agents for the Selective Detection and Killing of Light‐Accessible Melanotransferrin‐Expressing Melanoma and Triple‐Negative Breast Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70912

Vancouver

Magagoum SH, Biteghe FAN, Siwe GT, Lang D, Lekena N, Barth S. SNAP‐Tag–Based Recombinant Photoimmunotherapeutic Agents for the Selective Detection and Killing of Light‐Accessible Melanotransferrin‐Expressing Melanoma and Triple‐Negative Breast Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.70912

BibTeX
@article{Magagoum2025,
  author = {Magagoum, Suzanne Hippolite and Biteghe, Fleury Augustin Nsole and Siwe, Gael Tchokomeni and Lang, Dirk and Lekena, Nkhasi and Barth, Stefan},
  title = {SNAP‐Tag–Based Recombinant Photoimmunotherapeutic Agents for the Selective Detection and Killing of Light‐Accessible Melanotransferrin‐Expressing Melanoma and Triple‐Negative Breast Cancer},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70912}
}
Kostenlos starten →